Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

• Main Authors: Taha Koray Sahin (Author), Arif Akyildiz (Author), Osman Talha Dogan (Author), Gozde Kavgaci (Author), Deniz Can Guven (Author), Sercan Aksoy (Author)
• פורמט: ספר
• יצא לאור: MDPI AG, 2024-06-01T00:00:00Z.
• נושאים: article
• גישה מקוונת: Connect to this object online.

Trastuzumab emtansine (T-DM1) is a mainstay therapy for HER2-positive metastatic breast cancer (mBC). However, identifying patients who will benefit most remains a challenge due to the lack of reliable biomarkers. The recently developed pan-immune-inflammation value (PIV), a novel immune-inflammatio...